Biotech Insider Alert
by johnl49 | January 3, 2015 11:05 am
Touting a $4 Stock with $28M in sales that has a new drug in Phase trials for Uveitis – eye disease. It has been granted ”Orphan Status” by FDA[1] and Phase trial data is due out very soon. ?What is the stock and is this real? He wants $1950 for one year subscription to the newsletter.
Endnotes:
- FDA: https://www.stockgumshoe.com/tag/fda/
Source URL: https://www.stockgumshoe.com/2015/01/microblog-biotech-insider-alert/
Am interested also in learning about the company being promoted by Biotech Insider Alert because of a potential Uveitis cure.
I don’t know anything about the company but I do believe it is http://www.xoma.com
It is indeed XOMA and is old rehash previously covered by SGS
It seems a biotech drug from blue blood may change the science for cancer cure. No one knows what the drug name yet. If you keep an eye of publications they may cite this drug any time in future.
Not anytime soon. We covered that one here: http://www.stockgumshoe.com/reviews/alternative-energy-speculator/blue-blood-which-tiny-biotech-owns-only-source-of-rare-cancer-curing-chemical/